Australia markets open in 26 minutes

AVITA Medical, Inc. (AVH.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
4.1300+0.0800 (+1.98%)
At close: 04:10PM AEDT
Full screen
Previous close4.0500
Open4.1000
Bid4.0800 x 734600
Ask4.1400 x 258500
Day's range4.0300 - 4.2050
52-week range1.8800 - 6.2700
Volume308,245
Avg. volume239,109
Market cap528.979M
Beta (5Y monthly)1.54
PE ratio (TTM)N/A
EPS (TTM)-0.4100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.99
  • GlobeNewswire

    AVITA Medical to Host Investor Webinar Briefing

    VALENCIA, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on December 5, 2023, at 2:00 p.m. (PS

  • GlobeNewswire

    AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference

    VALENCIA, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the Piper Sandler 35th Annual Healthcare Conference in New York on Tuesday, November 28, 2023, at 1:00 p.m. Eastern Time. A live webcast of the present

  • GlobeNewswire

    AVITA Medical Updates Full Year 2023 Guidance

    VALENCIA, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced an update to its full year 2023 guidance. This update is a result of slower-than-anticipated progression through the customer’s Value Analysis Committee (VAC) processes, driven by the expanded label application